177 related articles for article (PubMed ID: 33981582)
1. Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II.
Yamamoto R; Yoden E; Tanaka N; Kinoshita M; Imakiire A; Hirato T; Minami K
Mol Genet Metab Rep; 2021 Jun; 27():100758. PubMed ID: 33981582
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacological property, mechanism of action and clinical study results of Pabinafusp Alfa (Genetical Recombination) (IZCARGO
Yamamoto R; Kawashima S
Nihon Yakurigaku Zasshi; 2022; 157(1):62-75. PubMed ID: 34980815
[TBL] [Abstract][Full Text] [Related]
3. Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in Brazil.
Giugliani R; Martins AM; So S; Yamamoto T; Yamaoka M; Ikeda T; Tanizawa K; Sonoda H; Schmidt M; Sato Y
Mol Ther; 2021 Jul; 29(7):2378-2386. PubMed ID: 33781915
[TBL] [Abstract][Full Text] [Related]
4. A Phase 2/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II.
Okuyama T; Eto Y; Sakai N; Nakamura K; Yamamoto T; Yamaoka M; Ikeda T; So S; Tanizawa K; Sonoda H; Sato Y
Mol Ther; 2021 Feb; 29(2):671-679. PubMed ID: 33038326
[TBL] [Abstract][Full Text] [Related]
5. Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis of Preclinical and Clinical Data.
Giugliani R; Martins AM; Okuyama T; Eto Y; Sakai N; Nakamura K; Morimoto H; Minami K; Yamamoto T; Yamaoka M; Ikeda T; So S; Tanizawa K; Sonoda H; Schmidt M; Sato Y
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681597
[TBL] [Abstract][Full Text] [Related]
6. Transferrin Receptor-Targeted Iduronate-2-sulfatase Penetrates the Blood-Retinal Barrier and Improves Retinopathy in Mucopolysaccharidosis II Mice.
Imakiire A; Morimoto H; Suzuki H; Masuda T; Yoden E; Inoue A; Morioka H; Konaka T; Mori A; Shirasaka R; Kato R; Hirato T; Sonoda H; Minami K
Mol Pharm; 2023 Nov; 20(11):5901-5909. PubMed ID: 37860991
[TBL] [Abstract][Full Text] [Related]
7. Analysis of caregiver perspectives on patients with mucopolysaccharidosis II treated with pabinafusp alfa: results of qualitative interviews in Japan.
Nakamura K; Sakai N; Hossain MA; Eisengart JB; Yamamoto T; Tanizawa K; So S; Schmidt M; Sato Y
Orphanet J Rare Dis; 2024 Mar; 19(1):104. PubMed ID: 38454486
[TBL] [Abstract][Full Text] [Related]
8. Dose-dependent effects of a brain-penetrating iduronate-2-sulfatase on neurobehavioral impairments in mucopolysaccharidosis II mice.
Morimoto H; Morioka H; Imakiire A; Yamamoto R; Hirato T; Sonoda H; Minami K
Mol Ther Methods Clin Dev; 2022 Jun; 25():534-544. PubMed ID: 35662814
[TBL] [Abstract][Full Text] [Related]
9. Divergent developmental trajectories in two siblings with neuropathic mucopolysaccharidosis type II (Hunter syndrome) receiving conventional and novel enzyme replacement therapies: A case report.
Tomita K; Okamoto S; Seto T; Hamazaki T; So S; Yamamoto T; Tanizawa K; Sonoda H; Sato Y
JIMD Rep; 2021 Nov; 62(1):9-14. PubMed ID: 34765392
[TBL] [Abstract][Full Text] [Related]
10. Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice.
Morimoto H; Kida S; Yoden E; Kinoshita M; Tanaka N; Yamamoto R; Koshimura Y; Takagi H; Takahashi K; Hirato T; Minami K; Sonoda H
Mol Ther; 2021 May; 29(5):1853-1861. PubMed ID: 33508431
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a HIR-Fab-IDS, Novel Iduronate 2-Sulfatase Fusion Protein for the Treatment of Neuropathic Mucopolysaccharidosis Type II (Hunter Syndrome).
Gusarova VD; Smolov MA; Lyagoskin IV; Degterev MB; Rechetnik EV; Rodionov AV; Pantyushenko MS; Shukurov RR
BioDrugs; 2023 May; 37(3):375-395. PubMed ID: 37014547
[TBL] [Abstract][Full Text] [Related]
12. A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II.
Sonoda H; Morimoto H; Yoden E; Koshimura Y; Kinoshita M; Golovina G; Takagi H; Yamamoto R; Minami K; Mizoguchi A; Tachibana K; Hirato T; Takahashi K
Mol Ther; 2018 May; 26(5):1366-1374. PubMed ID: 29606503
[TBL] [Abstract][Full Text] [Related]
13. Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial.
Okuyama T; Eto Y; Sakai N; Minami K; Yamamoto T; Sonoda H; Yamaoka M; Tachibana K; Hirato T; Sato Y
Mol Ther; 2019 Feb; 27(2):456-464. PubMed ID: 30595526
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS.
Tanaka N; Kida S; Kinoshita M; Morimoto H; Shibasaki T; Tachibana K; Yamamoto R
Mol Genet Metab; 2018 Sep; 125(1-2):53-58. PubMed ID: 30064964
[TBL] [Abstract][Full Text] [Related]
15. Insulin receptor antibody-iduronate 2-sulfatase fusion protein: pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys.
Boado RJ; Ka-Wai Hui E; Zhiqiang Lu J; Pardridge WM
Biotechnol Bioeng; 2014 Nov; 111(11):2317-25. PubMed ID: 24889100
[TBL] [Abstract][Full Text] [Related]
16. Effect of Anti-Iduronate 2-Sulfatase Antibodies in Patients with Mucopolysaccharidosis Type II Treated with Enzyme Replacement Therapy.
Vollebregt AAM; Hoogeveen-Westerveld M; Ruijter GJ; van den Hout H; Oussoren E; van der Ploeg AT; Pijnappel WWMP
J Pediatr; 2022 Sep; 248():100-107.e3. PubMed ID: 35568060
[TBL] [Abstract][Full Text] [Related]
17. Brain-penetrating IgG-iduronate 2-sulfatase fusion protein for the mouse.
Zhou QH; Boado RJ; Lu JZ; Hui EK; Pardridge WM
Drug Metab Dispos; 2012 Feb; 40(2):329-35. PubMed ID: 22065691
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and bioavailability of a therapeutic enzyme (idursulfase) in cynomolgus monkeys after intrathecal and intravenous administration.
Xie H; Chung JK; Mascelli MA; McCauley TG
PLoS One; 2015; 10(4):e0122453. PubMed ID: 25836678
[TBL] [Abstract][Full Text] [Related]
19. Effect of systemic high dose enzyme replacement therapy on the improvement of CNS defects in a mouse model of mucopolysaccharidosis type II.
Cho SY; Lee J; Ko AR; Kwak MJ; Kim S; Sohn YB; Park SW; Jin DK
Orphanet J Rare Dis; 2015 Oct; 10():141. PubMed ID: 26520066
[TBL] [Abstract][Full Text] [Related]
20. α-L-iduronidase fused with humanized anti-human transferrin receptor antibody (lepunafusp alfa) for mucopolysaccharidosis type I: A phase 1/2 trial.
Harmatz P; Giugliani R; Martins AM; Hamazaki T; Kubo T; Kira R; Minami K; Ikeda T; Moriuchi H; Kawashima S; Takasao N; So S; Sonoda H; Hirato T; Tanizawa K; Schmidt M; Sato Y
Mol Ther; 2024 Mar; 32(3):609-618. PubMed ID: 38204164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
